Human Fc gamma RIIIB / CD16b (NA1) Protein, His Tag (SPR & BLI & MALS verified)
分子别名（Synonym）
Fc gamma RIIIB，FCGR3B，CD16b (NA1)，CD16B，FCG3B，FCGR3，FCG3，IGFR3
表达区间及表达系统（Source）
Human CD16b (NA1), His Tag (CDB-H5227) is expressed from human HEK293 cells. It contains AA Gly 17 - Ser 200 (Accession # AAA35881.1). The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106.
Predicted N-terminus: Gly 17
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.8 kDa. The protein migrates as 35-45 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景（Background）
CD16是一种低亲和力Fc受体，已被鉴定为Fc受体FcγRIIIa（CD16a）和FcγRIII/b（CD16b）。这些受体与IgG抗体的Fc部分结合。CD16由两个不同的高度同源基因以细胞类型特异的方式编码。CD16存在于自然杀伤细胞、中性粒细胞、多形核白细胞、单核细胞和巨噬细胞的表面。CD16B也被称为FCGR3B和FCG3B，由多形核白细胞（中性粒细胞）和受刺激的嗜酸性粒细胞特异性表达。CD16B是免疫球蛋白γFc区的低亲和力受体。FCGR3B结合复合或聚集的IgG以及单体IgG。与III-A相反，FCG3B不能介导抗体依赖性细胞毒性和吞噬作用。CD16B可能作为外周循环中免疫复合物的陷阱，不会激活中性粒细胞。
关键字： Fc gamma RIIIB;CD16b蛋白;FCGR3B;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。